Copyright Reports & Markets. All rights reserved.

Global Hematological Malignancies Disease Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Hematological Malignancies Disease Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Hematological Malignancies Disease Market Size Growth Rate by Product
      • 1.4.2 Chemotherapy
      • 1.4.3 Immunotherapy
      • 1.4.4 Targeted Therapy
    • 1.5 Market by End User
      • 1.5.1 Global Hematological Malignancies Disease Market Size Growth Rate by End User
      • 1.5.2 Leukemia
      • 1.5.3 Lymphoma
      • 1.5.4 Myeloma
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Hematological Malignancies Disease Market Size
      • 2.1.1 Global Hematological Malignancies Disease Revenue 2014-2025
      • 2.1.2 Global Hematological Malignancies Disease Sales 2014-2025
    • 2.2 Hematological Malignancies Disease Growth Rate by Regions
      • 2.2.1 Global Hematological Malignancies Disease Sales by Regions
      • 2.2.2 Global Hematological Malignancies Disease Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Hematological Malignancies Disease Sales by Manufacturers
      • 3.1.1 Hematological Malignancies Disease Sales by Manufacturers
      • 3.1.2 Hematological Malignancies Disease Sales Market Share by Manufacturers
      • 3.1.3 Global Hematological Malignancies Disease Market Concentration Ratio (CR5 and HHI)
    • 3.2 Hematological Malignancies Disease Revenue by Manufacturers
      • 3.2.1 Hematological Malignancies Disease Revenue by Manufacturers (2014-2019)
      • 3.2.2 Hematological Malignancies Disease Revenue Share by Manufacturers (2014-2019)
    • 3.3 Hematological Malignancies Disease Price by Manufacturers
    • 3.4 Hematological Malignancies Disease Manufacturing Base Distribution, Product Types
      • 3.4.1 Hematological Malignancies Disease Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Hematological Malignancies Disease Product Type
      • 3.4.3 Date of International Manufacturers Enter into Hematological Malignancies Disease Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Hematological Malignancies Disease Sales by Product
    • 4.2 Global Hematological Malignancies Disease Revenue by Product
    • 4.3 Hematological Malignancies Disease Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Hematological Malignancies Disease Breakdown Data by End User

    6 North America

    • 6.1 North America Hematological Malignancies Disease by Countries
      • 6.1.1 North America Hematological Malignancies Disease Sales by Countries
      • 6.1.2 North America Hematological Malignancies Disease Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Hematological Malignancies Disease by Product
    • 6.3 North America Hematological Malignancies Disease by End User

    7 Europe

    • 7.1 Europe Hematological Malignancies Disease by Countries
      • 7.1.1 Europe Hematological Malignancies Disease Sales by Countries
      • 7.1.2 Europe Hematological Malignancies Disease Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Hematological Malignancies Disease by Product
    • 7.3 Europe Hematological Malignancies Disease by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Hematological Malignancies Disease by Countries
      • 8.1.1 Asia Pacific Hematological Malignancies Disease Sales by Countries
      • 8.1.2 Asia Pacific Hematological Malignancies Disease Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Hematological Malignancies Disease by Product
    • 8.3 Asia Pacific Hematological Malignancies Disease by End User

    9 Central & South America

    • 9.1 Central & South America Hematological Malignancies Disease by Countries
      • 9.1.1 Central & South America Hematological Malignancies Disease Sales by Countries
      • 9.1.2 Central & South America Hematological Malignancies Disease Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Hematological Malignancies Disease by Product
    • 9.3 Central & South America Hematological Malignancies Disease by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Hematological Malignancies Disease by Countries
      • 10.1.1 Middle East and Africa Hematological Malignancies Disease Sales by Countries
      • 10.1.2 Middle East and Africa Hematological Malignancies Disease Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Hematological Malignancies Disease by Product
    • 10.3 Middle East and Africa Hematological Malignancies Disease by End User

    11 Company Profiles

    • 11.1 Affymetrix
      • 11.1.1 Affymetrix Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Affymetrix Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Affymetrix Hematological Malignancies Disease Products Offered
      • 11.1.5 Affymetrix Recent Development
    • 11.2 SkylineDx
      • 11.2.1 SkylineDx Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 SkylineDx Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 SkylineDx Hematological Malignancies Disease Products Offered
      • 11.2.5 SkylineDx Recent Development
    • 11.3 AgenaBio
      • 11.3.1 AgenaBio Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 AgenaBio Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 AgenaBio Hematological Malignancies Disease Products Offered
      • 11.3.5 AgenaBio Recent Development
    • 11.4 Signal Genetics
      • 11.4.1 Signal Genetics Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Signal Genetics Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Signal Genetics Hematological Malignancies Disease Products Offered
      • 11.4.5 Signal Genetics Recent Development
    • 11.5 Cancer Genetics Inc
      • 11.5.1 Cancer Genetics Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Cancer Genetics Inc Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Cancer Genetics Inc Hematological Malignancies Disease Products Offered
      • 11.5.5 Cancer Genetics Inc Recent Development
    • 11.6 Illumina
      • 11.6.1 Illumina Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Illumina Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Illumina Hematological Malignancies Disease Products Offered
      • 11.6.5 Illumina Recent Development
    • 11.7 NeoGenomics
      • 11.7.1 NeoGenomics Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 NeoGenomics Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 NeoGenomics Hematological Malignancies Disease Products Offered
      • 11.7.5 NeoGenomics Recent Development
    • 11.8 Exiqon
      • 11.8.1 Exiqon Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Exiqon Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Exiqon Hematological Malignancies Disease Products Offered
      • 11.8.5 Exiqon Recent Development
    • 11.9 Regulus Therapeutics
      • 11.9.1 Regulus Therapeutics Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Regulus Therapeutics Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Regulus Therapeutics Hematological Malignancies Disease Products Offered
      • 11.9.5 Regulus Therapeutics Recent Development
    • 11.10 Rosetta Genomics
      • 11.10.1 Rosetta Genomics Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Rosetta Genomics Hematological Malignancies Disease Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Rosetta Genomics Hematological Malignancies Disease Products Offered
      • 11.10.5 Rosetta Genomics Recent Development
    • 11.11 Sequenta
    • 11.12 Takeda Pharma
    • 11.13 Celgene
    • 11.14 Amgen
    • 11.15 Ono Pharma
    • 11.16 Abbott
    • 11.17 BMS
    • 11.18 Mundipharma
    • 11.19 Novartis
    • 11.20 MorphoSys

    12 Future Forecast

    • 12.1 Hematological Malignancies Disease Market Forecast by Regions
      • 12.1.1 Global Hematological Malignancies Disease Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Hematological Malignancies Disease Revenue Forecast by Regions 2019-2025
    • 12.2 Hematological Malignancies Disease Market Forecast by Product
      • 12.2.1 Global Hematological Malignancies Disease Sales Forecast by Product 2019-2025
      • 12.2.2 Global Hematological Malignancies Disease Revenue Forecast by Product 2019-2025
    • 12.3 Hematological Malignancies Disease Market Forecast by End User
    • 12.4 North America Hematological Malignancies Disease Forecast
    • 12.5 Europe Hematological Malignancies Disease Forecast
    • 12.6 Asia Pacific Hematological Malignancies Disease Forecast
    • 12.7 Central & South America Hematological Malignancies Disease Forecast
    • 12.8 Middle East and Africa Hematological Malignancies Disease Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Hematological Malignancies Disease Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Hematological Malignancies Disease market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hematological Malignancies Disease market based on company, product type, end user and key regions.

      This report studies the global market size of Hematological Malignancies Disease in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hematological Malignancies Disease in these regions.
      This research report categorizes the global Hematological Malignancies Disease market by top players/brands, region, type and end user. This report also studies the global Hematological Malignancies Disease market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Affymetrix
      SkylineDx
      AgenaBio
      Signal Genetics
      Cancer Genetics Inc
      Illumina
      NeoGenomics
      Exiqon
      Regulus Therapeutics
      Rosetta Genomics
      Sequenta
      Takeda Pharma
      Celgene
      Amgen
      Ono Pharma
      Abbott
      BMS
      Mundipharma
      Novartis
      MorphoSys

      Market size by Product
      Chemotherapy
      Immunotherapy
      Targeted Therapy
      Market size by End User
      Leukemia
      Lymphoma
      Myeloma

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Hematological Malignancies Disease market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Hematological Malignancies Disease market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Hematological Malignancies Disease companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Hematological Malignancies Disease submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Hematological Malignancies Disease are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hematological Malignancies Disease market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now